DE60010662D1 - Kombinationen von formoterol und fluticasonpropionat für asthma - Google Patents

Kombinationen von formoterol und fluticasonpropionat für asthma

Info

Publication number
DE60010662D1
DE60010662D1 DE60010662T DE60010662T DE60010662D1 DE 60010662 D1 DE60010662 D1 DE 60010662D1 DE 60010662 T DE60010662 T DE 60010662T DE 60010662 T DE60010662 T DE 60010662T DE 60010662 D1 DE60010662 D1 DE 60010662D1
Authority
DE
Germany
Prior art keywords
fluticasonpropionate
formoterol
asthma
combinations
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Revoked
Application number
DE60010662T
Other languages
English (en)
Other versions
DE60010662T2 (de
Inventor
Guy Clarke
Luke Danahay
Francis Hassan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10848051&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE60010662(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis AG filed Critical Novartis AG
Publication of DE60010662D1 publication Critical patent/DE60010662D1/de
Application granted granted Critical
Publication of DE60010662T2 publication Critical patent/DE60010662T2/de
Anticipated expiration legal-status Critical
Revoked legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • A61K31/165Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • A61K31/165Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/007Pulmonary tract; Aromatherapy
    • A61K9/0073Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/007Pulmonary tract; Aromatherapy
    • A61K9/0073Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/007Pulmonary tract; Aromatherapy
    • A61K9/0073Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
DE60010662T 1999-02-18 2000-02-16 Kombinationen von formoterol und fluticasonpropionat für asthma Revoked DE60010662T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9903759.0A GB9903759D0 (en) 1999-02-18 1999-02-18 Organic compounds
GB9903759 1999-02-18
PCT/EP2000/001270 WO2000048587A1 (en) 1999-02-18 2000-02-16 Combinations of formoterol and fluticasone propionate for asthma

Publications (2)

Publication Number Publication Date
DE60010662D1 true DE60010662D1 (de) 2004-06-17
DE60010662T2 DE60010662T2 (de) 2005-05-19

Family

ID=10848051

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60010662T Revoked DE60010662T2 (de) 1999-02-18 2000-02-16 Kombinationen von formoterol und fluticasonpropionat für asthma

Country Status (32)

Country Link
US (4) US20020103260A1 (de)
EP (1) EP1152753B1 (de)
JP (1) JP2002537249A (de)
KR (2) KR20010102205A (de)
CN (1) CN1339965A (de)
AR (1) AR022609A1 (de)
AT (1) ATE266393T1 (de)
AU (1) AU758999B2 (de)
BR (1) BR0008276A (de)
CA (1) CA2368537A1 (de)
CO (1) CO5140098A1 (de)
CZ (1) CZ20012976A3 (de)
DE (1) DE60010662T2 (de)
DK (1) DK1152753T3 (de)
ES (1) ES2220411T3 (de)
GB (1) GB9903759D0 (de)
HK (1) HK1042429A1 (de)
HU (1) HUP0200852A3 (de)
ID (1) ID29437A (de)
IL (1) IL144061A (de)
MY (1) MY126768A (de)
NO (1) NO20013987D0 (de)
NZ (1) NZ513526A (de)
PE (1) PE20001545A1 (de)
PL (1) PL349856A1 (de)
PT (1) PT1152753E (de)
RU (1) RU2249454C2 (de)
SK (1) SK11842001A3 (de)
TR (1) TR200102110T2 (de)
TW (1) TWI229601B (de)
WO (1) WO2000048587A1 (de)
ZA (1) ZA200105391B (de)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9616237D0 (en) 1996-08-01 1996-09-11 Norton Healthcare Ltd Aerosol formulations
GB2392915B (en) * 1999-09-11 2004-04-28 Glaxo Group Ltd Pharmaceutical formulation of fluticasone propionate
GB2385596B (en) * 1999-09-11 2004-03-03 Glaxo Group Ltd Container for pharmaceutical formulation of fluticasone propionate
DE60031504T2 (de) 1999-09-11 2007-04-05 Glaxo Group Ltd., Greenford Fluticasonpropionat arzneizubereitung
JP2003531123A (ja) * 2000-04-13 2003-10-21 イノバータ・バイオミッド・リミテッド 医薬品
GB0009591D0 (en) * 2000-04-18 2000-06-07 Glaxo Group Ltd Medical combinations
GB0012260D0 (en) 2000-05-19 2000-07-12 Astrazeneca Ab Novel composition
US6759398B2 (en) * 2000-08-05 2004-07-06 Smithkline Beecham Corporation Anti-inflammatory androstane derivative
FI20002216A0 (fi) 2000-10-06 2000-10-06 Orion Yhtymae Oyj Yhdistelmäpartikkelit astman hoitoon
FI20002215A0 (fi) 2000-10-06 2000-10-06 Orion Yhtymae Oyj Yhdistelmäpartikkelit
PL365736A1 (en) * 2001-02-06 2005-01-10 Innovata Biomed Limited Bimodal dry powder formulation for inhalation
GB0106031D0 (en) * 2001-03-12 2001-05-02 Glaxo Group Ltd Use
CZ301676B6 (cs) * 2001-03-30 2010-05-19 Jagotec Ag Farmaceutický suspenzní aerosolový prípravek pro inhalaci a použití soli karboxylové kyseliny
US20030055026A1 (en) * 2001-04-17 2003-03-20 Dey L.P. Formoterol/steroid bronchodilating compositions and methods of use thereof
US6667344B2 (en) 2001-04-17 2003-12-23 Dey, L.P. Bronchodilating compositions and methods
US7931022B2 (en) 2001-10-19 2011-04-26 Respirks, Inc. Method and apparatus for dispensing inhalator medicament
WO2003066033A1 (en) 2002-02-04 2003-08-14 Glaxo Group Limited Formulation for inhalation comprising a glucocorticoid and a beta 2-adrenoreceptor agonist
EP1757281A3 (de) * 2002-02-04 2009-07-15 Glaxo Group Limited Zubereitung zur Inhalation enthaltend ein Glucocorticoid und einen Beta 2-Adrenorezeptor Agonisten
GB2389530B (en) 2002-06-14 2007-01-10 Cipla Ltd Pharmaceutical compositions
GB0219511D0 (en) * 2002-08-21 2002-10-02 Norton Healthcare Ltd Method of preparing dry powder inhalation compositions
US20050158248A1 (en) * 2002-08-21 2005-07-21 Xian-Ming Zeng Method of preparing dry powder inhalation compositions
JP4744876B2 (ja) * 2002-08-21 2011-08-10 ノートン・ヘルスケアー リミテッド 乾燥粉末吸入組成物の製造方法
US8273331B2 (en) 2002-08-21 2012-09-25 Norton Healthcare Ltd. Inhalation compositions
WO2004028545A1 (en) * 2002-09-25 2004-04-08 Astrazeneca Ab A COMBINATION OF A LONG-ACTING β2-AGONIST AND A GLUCOCORTICOSTEROID IN THE TREATMENT OF FIBROTIC DISEASES
SE527069C2 (sv) 2003-06-19 2005-12-13 Mederio Ag Förfarande och anordning för administrering av läkemedelspulver
SE526509C2 (sv) * 2003-06-19 2005-09-27 Microdrug Ag Kombinerade doser av formoterol och budesonid separerade på en gemensam dosbädd
SE527200C2 (sv) * 2003-06-19 2006-01-17 Microdrug Ag Inhalatoranordning samt kombinerade doser av formaterol och fluticason
SE527189C2 (sv) * 2003-06-19 2006-01-17 Microdrug Ag Inhalatoranordning samt kombinerade doser för formaterol och ett antikolinergiskt medel
SE526850C2 (sv) * 2003-06-19 2005-11-08 Microdrug Ag Farmaceutisk kombinerad torr pulverdos separerade på gemensam dosbädd
TWI359675B (en) * 2003-07-10 2012-03-11 Dey L P Bronchodilating β-agonist compositions
GB0323685D0 (en) * 2003-10-09 2003-11-12 Jagotec Ag Improvements in or relating to organic compounds
GB0323684D0 (en) * 2003-10-09 2003-11-12 Jagotec Ag Improvements in or relating to organic compounds
GB0617171D0 (en) * 2006-08-31 2006-10-11 Generics Uk Ltd Novel compositions and methods
WO2008137446A1 (en) * 2007-05-03 2008-11-13 Trustees Of Boston University Methods and compositions for the treatment of respiratory disease
US8815258B2 (en) 2009-05-29 2014-08-26 Pearl Therapeutics, Inc. Compositions, methods and systems for respiratory delivery of two or more active agents
CN107412212B (zh) 2009-05-29 2021-01-22 珍珠治疗公司 经肺递送长效毒蕈碱拮抗剂及长效β2肾上腺素能受体激动剂的组合物及相关方法与系统
GB0918150D0 (en) * 2009-10-16 2009-12-02 Jagotec Ag Improved formulations
GB0918149D0 (en) 2009-10-16 2009-12-02 Jagotec Ag Improved medicinal aerosol formulation
WO2011093811A2 (en) * 2010-01-29 2011-08-04 Mahmut Bilgic Pharmaceutical preparations comprising formoterol and fluticasone
WO2012049444A1 (en) * 2010-10-12 2012-04-19 Cipla Limited Pharmaceutical composition
SG194896A1 (en) * 2011-05-17 2013-12-30 Pearl Therapeutics Inc Compositions, methods & systems for respiratory delivery of two or more active agents
KR20150002774A (ko) 2012-04-11 2015-01-07 시플라 리미티드 아르포르모테롤 및 플루티카손 푸로에이트를 포함하는 약학 조성물
RU2696582C2 (ru) 2013-03-15 2019-08-05 Перл Терапьютикс, Инк. Способы и системы кондиционирования дисперсных кристаллических материалов

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL95590A (en) * 1989-09-08 1996-06-18 Glaxo Group Ltd Medicinal preparations containing Salmetrol and Pluticasone Propionate
SE9302777D0 (sv) * 1993-08-27 1993-08-27 Astra Ab Process for conditioning substances
US5658549A (en) * 1991-12-12 1997-08-19 Glaxo Group Limited Aerosol formulations containing propellant 134a and fluticasone propionate
AU673660C (en) * 1991-12-18 2002-07-25 Astrazeneca Ab New combination of formoterol and budesonide
GB9426252D0 (en) * 1994-12-24 1995-02-22 Glaxo Group Ltd Pharmaceutical composition
SE9700135D0 (sv) * 1997-01-20 1997-01-20 Astra Ab New formulation
DK1014943T3 (da) * 1997-02-05 2002-10-14 Jago Res Ag Medicinske aerosolformuleringer
WO1998041193A1 (en) * 1997-03-20 1998-09-24 Schering Corporation Preparation of powder agglomerates

Also Published As

Publication number Publication date
HUP0200852A2 (en) 2002-08-28
US20020103260A1 (en) 2002-08-01
EP1152753A1 (de) 2001-11-14
MY126768A (en) 2006-10-31
BR0008276A (pt) 2001-11-06
ATE266393T1 (de) 2004-05-15
CZ20012976A3 (cs) 2001-11-14
KR20070104955A (ko) 2007-10-29
ZA200105391B (en) 2002-06-21
TWI229601B (en) 2005-03-21
PL349856A1 (en) 2002-09-23
PT1152753E (pt) 2004-09-30
NZ513526A (en) 2004-01-30
TR200102110T2 (tr) 2001-10-22
AR022609A1 (es) 2002-09-04
ES2220411T3 (es) 2004-12-16
WO2000048587A1 (en) 2000-08-24
DK1152753T3 (da) 2004-08-16
US20040101487A1 (en) 2004-05-27
RU2249454C2 (ru) 2005-04-10
NO20013987L (no) 2001-08-16
US20100034890A1 (en) 2010-02-11
CN1339965A (zh) 2002-03-13
CO5140098A1 (es) 2002-03-22
IL144061A (en) 2005-12-18
EP1152753B1 (de) 2004-05-12
ID29437A (id) 2001-08-30
US20050287079A1 (en) 2005-12-29
GB9903759D0 (en) 1999-04-14
JP2002537249A (ja) 2002-11-05
PE20001545A1 (es) 2001-01-29
AU2911500A (en) 2000-09-04
KR20010102205A (ko) 2001-11-15
NO20013987D0 (no) 2001-08-16
HK1042429A1 (en) 2002-08-16
HUP0200852A3 (en) 2004-04-28
SK11842001A3 (sk) 2001-12-03
CA2368537A1 (en) 2000-08-24
DE60010662T2 (de) 2005-05-19
AU758999B2 (en) 2003-04-03
IL144061A0 (en) 2002-04-21

Similar Documents

Publication Publication Date Title
DE60010662D1 (de) Kombinationen von formoterol und fluticasonpropionat für asthma
EE04297B1 (et) Budesoniidi ja formoterooli uus kasutamine
ATE252832T1 (de) Kombinationen aus herbiziden und safenern
DE69908339D1 (de) Endgerät für bibliotheken und dergleichen
DE59903869D1 (de) Verwendung von nanoskaligen sterolen und sterolestern
DE69924155D1 (de) Fluoren-copolymere und daraus hergestellte vorrichtungen
DE60012644D1 (de) Kombination aus Aescin und Dextran Sulphat
DE60017293D1 (de) Werkstoffe für Dichtungen und Beilagscheiben von verstellbaren Leitschaufeln
DE59912795D1 (de) Substituierte Benzamide und ihre Verwendung als Immunmodulatoren
ID30430A (id) Senyawa-senyawa dan metode-metode untuk pengobatan gangguan-gangguan asma, alergi dan inflamasi
DE69903961T2 (de) Muscarinagonisten und antagonisten
DE69934889D1 (de) Herstellung und reinigung von diboranen
DE69826008D1 (de) Mischungen aus polyimiden und elastomeren
ID28368A (id) Tanda-tanda mikrosatelite tumbuhan dan metode terhadap penggunaannya
DE69932653D1 (de) Dielektrisches Filter und dielektrischer Duplexer
DE69841337D1 (de) Hebestrukturen und anordnungen dafür
NO996438D0 (no) Ny kombinasjon av astmamedikamenter
DE69900802D1 (de) MnMgCuZn-Ferrit und dessen Verwendung
IT1319105B1 (it) Procedimento per fabbricare opuscoli e dispositivo per l'esecuzionedel procedimento
DE60131595D1 (de) Trennwand für Aufenthaltsräume und dessen Gebrauch
DE69825320D1 (de) Wärmeisolationsmaterial für gebäude und anwendung dessselben
DE29900576U1 (de) Nasenspülkanne und Nasenspülset
ATA12862000A (de) Gas- und/oder flüssigkeitsdurchlässiges filtermaterial
DE29805120U1 (de) Anordnung zur Konstruktion und Gestaltung von Deponien
DE60236080D1 (de) Verhinderung des verlusts von portoguthaben für frankiermaschinen und pc-frankiermaschinen

Legal Events

Date Code Title Description
8363 Opposition against the patent
8331 Complete revocation